How Do PARP Inhibitors Work for BRCA-Mutated Cancers?

PARP inhibitors (such as olaparib, rucaparib, niraparib, and talazoparib) are oral medications that take advantage of a specific weakness in BRCA-mutated cancer cells ^[1]. They are frequently used to treat BRCA-related ovarian, breast, prostate, and pancreatic cancers ^[2]. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, PARP inhibitors are designed to selectively target the cancer cells ^[3]. They achieve this through a biological concept called synthetic lethality, effectively cutting off the cancer cell’s last remaining way to repair its own DNA ^[4].

The “Two-Engine” Analogy: What is Synthetic Lethality?

To understand synthetic lethality, imagine a dual-engine airplane.

• If one engine fails, the plane can still fly safely using the backup engine.
• If both engines fail simultaneously, the plane will crash.

In your body, your cells are constantly experiencing minor DNA damage just from everyday living ^[5]. To survive, cells have multiple “engines” (pathways) to repair this DNA damage.

• The BRCA genes (BRCA1 and BRCA2) control one major repair engine, called homologous recombination ^[1].
• The PARP proteins (poly-ADP ribose polymerase) control a different, backup repair engine ^[6].

In a person with a BRCA-mutated cancer, the cancer cells have a broken BRCA “engine.” They can’t fix DNA damage using their main pathway ^[1]. However, they survive because they rely heavily on their backup engine: the PARP pathway ^[7].

When you take a PARP inhibitor, the drug shuts down the backup PARP engine ^[4]. For the BRCA-mutated cancer cells, losing both engines is catastrophic. Without any way to repair their DNA, the damage piles up rapidly and the cancer cell dies ^[5]. This simultaneous loss of two pathways causing cell death is what doctors mean by synthetic lethality ^[8].

Why Do Normal Cells Survive?

A common concern is whether PARP inhibitors will destroy healthy cells along with the cancer.

Even if you have an inherited (germline) BRCA mutation, your normal, healthy cells usually still have one working copy of the BRCA gene ^[3]. This means their BRCA DNA repair “engine” still works.

When the PARP inhibitor shuts down the PARP pathway in your whole body, your healthy cells can fall back on their working BRCA pathway to repair themselves and survive ^[3]. Only the cancer cells, which have completely lost BRCA function, are selectively targeted by the drug ^[1].

Are There Side Effects?

While PARP inhibitors are targeted to spare most normal cells, they are not completely side-effect-free. Some healthy cells—especially rapidly dividing cells in your bone marrow—can still be affected ^[3]. Because of this, you take PARP inhibitors as daily pills at home, but your doctor will require regular blood tests to monitor your health ^[2].

Common side effects include fatigue, nausea, and changes in your blood counts, such as anemia (low red blood cells) or neutropenia (low white blood cells) ^[9]. In rare cases, PARP inhibitors can cause more severe bone marrow problems ^[2]. Your care team can adjust your dosage or give you short breaks from the medication to allow your healthy cells time to recover.

“PARP Trapping”: Gluing the Machine to the DNA

Scientists have discovered that PARP inhibitors do more than just turn off the PARP repair engine ^[10]. They also cause a phenomenon known as PARP trapping ^[7].

Normally, the PARP protein acts like a mechanic, temporarily binding to damaged DNA to coordinate repairs before detaching ^[6]. A PARP inhibitor acts like superglue, trapping the PARP protein directly onto the DNA strand so it can’t let go ^[11].

This trapped protein creates a physical roadblock ^[12]. When the cancer cell tries to copy its DNA to multiply, it crashes into these roadblocks ^[13]. This creates massive structural damage (converting minor single-strand breaks into severe double-strand breaks) that the BRCA-deficient cancer cell is entirely unable to fix, accelerating its death ^[5][13].

Monitoring Your Progress

Because cancers can adapt over time, your doctor will closely monitor how well the PARP inhibitor is working using regular scans or blood tests, like tumor markers ^[9].

Sometimes, the cancer might eventually stop responding to the drug. This can happen if the cancer cells undergo secondary mutations that actually restore their broken BRCA “engine,” allowing them to repair DNA again ^[14]. Other times, the cancer cells develop “pumps” that actively push the drug out of the cell before it can work ^[15]. If this happens, your doctor may recommend switching to a different therapy or exploring clinical trials that are testing new ways to overcome this resistance ^[16].